MedTrace Logo

GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles

NCT00516490 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 570

Last updated 2007-08-15

No results posted yet for this study

Summary

A single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles was reported to increase pregnancy and birth rates. This study was done to evaluate the reproducibility of previous findings.

Conditions

Interventions

DRUG

triptorelin acetate

Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer

DRUG

Na Cl %0.9

0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer

Sponsors & Collaborators

  • V.K.V. American Hospital, Istanbul

    lead OTHER

Principal Investigators

  • Baris Ata, M.D. · The Assisted Reproduction Unit of the American Hospital of Istanbul

  • Bulent Urman, M.D. · The Assisted Reproduction Unit of the American Hospital of Istanbul

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2007-07-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00516490 on ClinicalTrials.gov